{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T06:53:18Z","timestamp":1780987998326,"version":"3.54.1"},"reference-count":87,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T00:00:00Z","timestamp":1743206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The introduction of bispecific antibodies (BsAbs) has led to significant improvements in survival for patients with relapsed and refractory B-cell lymphomas. Despite these advances, there remains a significant number of patients who experience disease progression after these novel therapies. Predicting which patients may respond to certain treatments and the durability of their responses remains challenging. Measurable residual disease (MRD) has become easier to detect and quantify through the use of genomic next-generation sequencing tools and has been studied as a possible biomarker to predict long-term outcomes and risk-stratify patients after BsAb therapy in several lymphoma subtypes. Here, we review recent data demonstrating that MRD negativity is associated with radiographic response and improved progression-free survival. Because of heterogeneity in assay choice, assessment timing, and technical parameters, further work is needed before MRD testing is ready to be incorporated into clinical practice in the context of BsAb treatment for B-cell lymphomas.<\/jats:p>","DOI":"10.3390\/cancers17071153","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T01:59:36Z","timestamp":1743386376000},"page":"1153","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Measurable Residual Disease Testing During Treatment with Bispecific Antibodies for Lymphoma"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6483-6542","authenticated-orcid":false,"given":"Gaston","family":"Jean-Louis","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Columbia University Irving Medical Center, New York, NY 10032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8266-8447","authenticated-orcid":false,"given":"Hua-Jay J.","family":"Cherng","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Columbia University Irving Medical Center, New York, NY 10032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/s41591-021-01622-0","article-title":"Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: The phase 2 ELARA trial","volume":"28","author":"Fowler","year":"2021","journal-title":"Nat. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_9","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or re-fractory aggressive B-cell lymphomas (JULIET): A multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood.2023020854","article-title":"Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001","volume":"143","author":"Abramson","year":"2024","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1200\/JCO.21.00377","article-title":"Monitoring of Circulating Tumor DNA Improves Early Relapse Detection After Axicabtagene Ciloleucel Infusion in Large B-Cell Lymphoma: Results of a Prospective Multi-Institutional Trial","volume":"39","author":"Frank","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ccell.2022.12.005","article-title":"Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas","volume":"41","author":"Sworder","year":"2022","journal-title":"Cancer Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood.2023021243","article-title":"Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5)","volume":"143","author":"Neelapu","year":"2024","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1182\/blood.2023021567","article-title":"Durable response after tisagenlecleucel in adults with relapsed\/refractory follicular lymphoma: ELARA trial update","volume":"143","author":"Dreyling","year":"2024","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1182\/hematology.2023000438","article-title":"Selection of bispecific antibody therapies or CAR-T cell therapy in relapsed lymphomas","volume":"2023","author":"Major","year":"2023","journal-title":"Hematology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1200\/JCO.23.02786","article-title":"Five-Year Follow-Up of Standard-of-Care Axicabtagene Ciloleucel for Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium","volume":"42","author":"Jain","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II Trial of the Anti-CD19 Bispecific T Cell\u2013Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific antibodies for the treatment of B-cell lympho-ma: Promises, unknowns, and opportunities","volume":"141","author":"Falchi","year":"2023","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients with Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study","volume":"40","author":"Budde","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with re-lapsed or refractory follicular lymphoma: A single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: An open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell\u2013Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I\/II Trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): A phase 2 cohort of a single-arm, multicentre study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","article-title":"Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial","volume":"38","author":"Thieblemont","year":"2024","journal-title":"Leukemia"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell\u2013Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a human CD20:D3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): Results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.annonc.2024.08.2239","article-title":"Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma\u2606","volume":"35","author":"Kim","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, stag-ing, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1182\/bloodadvances.2022009426","article-title":"Circulating tumor DNA adds specificity to PET after axicabtagene ciloleucel in large B-cell lymphoma","volume":"7","author":"Dean","year":"2023","journal-title":"Blood Adv."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Russler-Germain, D.A., and Ghobadi, A. (2023). T-cell redirecting therapies for B-cell non-Hodgkin lymphoma: Recent progress and future directions. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1168622"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e433516","DOI":"10.1200\/EDBK_433516","article-title":"Bispecific Antibody Use in Patients With Lymphoma and Multiple Myeloma","volume":"44","author":"Braun","year":"2024","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s11899-023-00715-6","article-title":"Measurable Residual Disease Monitoring in Lymphoma","volume":"18","author":"Cuzzo","year":"2023","journal-title":"Curr. Hematol. Malign. Rep."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Benintende, G., Pozzo, F., Innocenti, I., Autore, F., Fresa, A., D\u2019arena, G., Gattei, V., and Laurenti, L. (2023). Measurable residual disease in chronic lymphocytic leukemia. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1112616"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1200\/JCO.2017.76.8671","article-title":"Circulating Tumor DNA Analysis in Patients with Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review","volume":"36","author":"Merker","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/annonc\/mdp006","article-title":"Cell-free circulating DNA in Hodgkin\u2019s and non-Hodgkin\u2019s lymphomas","volume":"20","author":"Hohaus","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nm.1789","article-title":"Circulating mutant DNA to assess tumor dynamics","volume":"14","author":"Diehl","year":"2008","journal-title":"Nat. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","article-title":"Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing","volume":"125","author":"Kurtz","year":"2015","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1182\/blood-2017-03-735639","article-title":"High-throughput sequencing for noninvasive disease detection in hematologic malignancies","volume":"130","author":"Scherer","year":"2017","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Taylor, S.C., Laperriere, G., and Germain, H. (2017). Droplet Digital PCR versus qPCR for gene expression analysis with low abundant targets: From variable nonsense to publication quality data. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-02217-x"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/humu.22825","article-title":"Evaluation of Hybridization Capture Versus Amplicon-Based Methods for Whole-Exome Sequencing","volume":"36","author":"Samorodnitsky","year":"2015","journal-title":"Hum. Mutat."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: A correlative biomarker study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1186\/s12885-020-07077-9","article-title":"Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma","volume":"20","author":"Ching","year":"2020","journal-title":"BMC Cancer"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"364ra155","DOI":"10.1126\/scitranslmed.aai8545","article-title":"Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA","volume":"8","author":"Scherer","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"9257","DOI":"10.1182\/blood-2022-162814","article-title":"Detection of Early Molecular Response (EMR) and Minimal Residual Disease (MRD) in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Using a Validated Next Generation Sequencing (NGS) Assay for the Detection of Tumor Variants in Circulating Tumor (ct) DNA","volume":"140","author":"Stokowski","year":"2022","journal-title":"Blood"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","article-title":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","volume":"39","author":"Kurtz","year":"2021","journal-title":"Nat. Biotechnol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/s41591-020-0915-3","article-title":"Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring","volume":"26","author":"Zviran","year":"2020","journal-title":"Nat. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/s41467-017-00965-y","article-title":"Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors","volume":"8","author":"Adalsteinsson","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3324\/haematol.2020.268813","article-title":"Shallow-depth sequencing of cell-free DNA for Hodgkin and diffuse large B-cell lymphoma (differential) diagnosis: A standardized approach with underappreciated potential","volume":"107","author":"Raman","year":"2020","journal-title":"Haematologica"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1182\/blood.2022015601","article-title":"Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma","volume":"140","author":"Cherng","year":"2022","journal-title":"Blood"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"4376","DOI":"10.1182\/blood-2023-186603","article-title":"Role of Circulating Tumor DNA As a Prognostic Biomarker in Patients with Diffuse Large B-Cell Lymphoma","volume":"142","author":"Narkhede","year":"2023","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1182\/blood-2023-189962","article-title":"A Personalized Whole Genome-Informed Assay Targeting Single Mutant in Circulating Tumor DNA Can Identify MRD and Predict Relapse in DLBCL","volume":"142","author":"Merryman","year":"2023","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/hon.3164_232","article-title":"Evaluation of ctDNA in a phase I\/II trial in relapsed or refractory large B-cell lym-phoma of epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell\u2013engaging antibody","volume":"41","author":"Soong","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1097\/01.HS9.0000847704.12245.1f","article-title":"Immune Correlates of Response to Glofitamab: Biomarker Findings from a Pivotal Phase II Expansion Study in Patients with Relapsed or Refractory (R\/R) Diffuse Large B-Cell Lymphoma (DLBCL)","volume":"6","author":"Piccione","year":"2022","journal-title":"Hemasphere"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4356","DOI":"10.1182\/blood-2024-207596","article-title":"Early Assessment of Circulating Tumor (ct)DNA and Analysis of TP53 mutations in Patients with Relapsed\/Refractory (R\/R) Large B-Cell Lymphoma Treated with Glofitamab Monotherapy","volume":"144","author":"Zucchinetti","year":"2024","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_60","unstructured":"Carlo-Stella, C., Leung, W., Dickinson, M., Bachy, E., Morschhauser, F., Corradini, P., Garcia-Calvo, G.I.I., Trneny, M., Wr\u00f3bel, T., and Wu, S.J. (2024, January 14). Response in Molecular Subgroups and Circulating Tumor (ct)DNA Kinetics in Patients with Relapsed and\/or Refractory (R\/R) Large B-cell Lymphoma (LBCL) Treated with Glofitamab Monotherapy. Proceedings of the European Hematology Association (EHA) Annual Meeting, Madrid, Spain."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2024-194333","article-title":"Fixed-Duration Glofitamab Monotherapy Continues to Demonstrate Durable Responses in Patients with Relapsed or Refractory Large B-Cell Lymphoma: 3-Year Follow-up from a Pivotal Phase II Study","volume":"144","author":"Dickinson","year":"2024","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/blood-2023-179812","article-title":"Circulating Tumor DNA Analysis Associates with Progression-Free Survival (PFS) with Odronextamab Monotherapy in Relapsed\/Refractory (R\/R) Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL): Identification of Minimal Residual Disease Status and High-Risk Subgroups from the Phase 2 ELM-2 Study","volume":"142","author":"Arnason","year":"2023","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1182\/blood-2024-193681","article-title":"Evaluation of AZD0486, a Novel CD19xCD3 T-Cell Engager, in Relapsed\/Refractory Diffuse Large B-Cell Lymphoma in an Ongoing First-in-Human Phase 1 Study: High Complete Re-sponses Seen in CAR-T-Naive and CAR-T-Exposed Patients","volume":"144","author":"Gaballa","year":"2024","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1182\/blood-2024-199271","article-title":"Epcore DLBCL-3 First Disclosure: Fixed-Duration Epcoritamab Monotherapy in Older (\u226575 y), Anthracycline-Ineligible Patients with Previously Untreated Large B-Cell Lympho-ma","volume":"144","author":"Morschhauser","year":"2024","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1182\/blood-2024-198023","article-title":"Fixed-Duration Epcoritamab + R-CHOP Induces High Complete Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Withhigh-Risk Features: Long-Term Results from the Epcore NHL-2 Trial","volume":"144","author":"Falchi","year":"2024","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"3106","DOI":"10.1182\/blood-2024-199652","article-title":"Fixed-Duration Epcoritamab + R-Mini-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Ineligible for Full-Dose R-CHOP: Updated Results from Arm 8 of the Epcore NHL-2 Trial","volume":"144","author":"Leslie","year":"2024","journal-title":"Blood"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1182\/blood-2024-200395","article-title":"Immune Biomarkers of Mechanism of Action of Epcoritamab (Epcor) Plus Po-latuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) in Frontline DLBCL","volume":"144","author":"Dixit","year":"2024","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1182\/blood-2024-199301","article-title":"Fixed-Duration Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from Arm 1 of the Epcore NHL-5 Trial","volume":"144","author":"Gurion","year":"2024","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1182\/blood-2024-204930","article-title":"A Randomized Phase 2, Investigator-Led Trial of Glofitamab-R-CHOP or Glofitamab-Polatuzumab Vedotin-R-CHP (COALITION) in Younger Patients with High Burden, High-Risk Large B-Cell Lymphoma Demonstrates Safety, Uncompromised Chemotherapy Intensity, a High Rate of Durable Remissions, and Unique FDG-PET Response Characteristics","volume":"144","author":"Minson","year":"2024","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1182\/blood-2023-174081","article-title":"Glofitamab Plus R-CHOP Induces High Response Rates with a Manageable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A 12-Month Analysis from a Phase Ib Study","volume":"142","author":"Topp","year":"2023","journal-title":"Blood"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1182\/blood-2024-194328","article-title":"Glofitamab in Combination with Polatuzumab Vedotin Maintains Durable Responses and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed\/Refractory (R\/R) Large B-Cell Lymphoma (LBCL) Including High-Grade B-Cell Lymphoma (HGBCL): Extended Follow-up of a Phase Ib\/II Study","volume":"144","author":"Hutchings","year":"2024","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3017","DOI":"10.1182\/blood-2023-173677","article-title":"Englumafusp Alfa (CD19-4-1BBL) and Glofitamab Combination in Patients with Relapsed\/Refractory Non-Hodgkin Lymphoma (R\/R NHL): Biomarker Results from a Phase I Dose-Escalation Trial","volume":"142","author":"Korfi","year":"2023","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1182\/blood-2024-200096","article-title":"Englumafusp Alfa (CD19-4-1BBL) Combined with Glofitamab Is Safe and Efficacious in Patients with r\/r B-NHL: Extended Follow up Analysis of the Dose-Escalation Part of Phase 1 Trial BP41072","volume":"144","author":"Hutchings","year":"2024","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1182\/blood-2024-193589","article-title":"Escalating Doses of AZD0486, a Novel CD19xCD3 T-Cell Engager, Result in High Complete Remissions with Rapid Clearance of Minimal Residual Disease in Patients with Re-lapsed\/Refractory Follicular Lymphoma","volume":"144","author":"Hou","year":"2024","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1182\/blood-2024-200018","article-title":"Glofitamab Induces High Response Rates and Durable Remissions in Patients (Pts) with Heavily Pretreated Relapsed\/Refractory (R\/R) Mantle Cell Lymphoma (MCL), Including Those with a Poor Prognosis: Subgroup Results from a Phase I\/II Study","volume":"144","author":"Phillips","year":"2024","journal-title":"Blood"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1182\/blood-2024-199708","article-title":"Epcoritamab Monotherapy in Patients (Pts) with Relapsed or Refractory (R\/R) Chronic Lymphocytic Leukemia (CLL): Results from CLL Expansion and Optimization Cohorts of Epcore CLL-1","volume":"144","author":"Danilov","year":"2024","journal-title":"Blood"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.1182\/blood-2024-202085","article-title":"Mosunetuzumab Plus Polatuzumab Vedotin Induces Early Complete Responses in Previously Untreated High Tumor Burden Follicular Lymphoma","volume":"144","author":"Wan","year":"2024","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1182\/blood-2024-200262","article-title":"Fixed-Duration Epcoritamab + R2 Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial","volume":"144","author":"Falchi","year":"2024","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating Tumor DNA Measurements as Early Outcome Predictors in Diffuse Large B-Cell Lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1182\/blood-2023-173953","article-title":"Glofitamab (Glofit) Plus R-CHOP Has a Favorable Safety Profile and Induces High Response Rates in Patients with Previously Untreated (1L) Large B-Cell Lymphoma (LBCL) Defined As High Risk By Circulating Tumor DNA (ctDNA) Dynamics: Preliminary Safety and Efficacy Results","volume":"142","author":"Falchi","year":"2023","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"7015","DOI":"10.1200\/JCO.2024.42.16_suppl.7015","article-title":"EPCORE NHL-1 follicular lymphoma (FL) cycle (C) 1 optimization (OPT) cohort: Expanding the clinical utility of epcoritamab in relapsed or refractory (R\/R) FL","volume":"42","author":"Vose","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1158\/1538-7445.AM2024-5071","article-title":"Minimal residual disease (MRD) status by peripheral blood mono-nuclear cells (PBMCs) and circulating tumor DNA (ctDNA) demonstrates rapid, deep, and sustained response in patients (Pts) with relapsed\/refractory follicular lymphoma (R\/R FL) treated with sub-cutaneous (SC) epcoritamab monotherapy in the pivotal phase 1\/2 EPCORE\u2122 NHL-1 trial","volume":"84","author":"Soong","year":"2024","journal-title":"Cancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"31904","DOI":"10.18632\/oncotarget.25881","article-title":"Investigation of appropriate pre-analytical procedure for circulating free DNA from liquid biopsy","volume":"9","author":"Sato","year":"2018","journal-title":"Oncotarget"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.clinbiochem.2016.03.012","article-title":"Comparative analysis of circulating tumor DNA stability In K3EDTA, Streck, and CellSave blood collection tubes","volume":"49","author":"Kang","year":"2016","journal-title":"Clin. Biochem."},{"key":"ref_85","unstructured":"(2025, February 13). National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: B-Cell Lymphomas. Version 2.2025; National Comprehensive Cancer Network: Plymouth Meeting, PA, USA. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/hon.2704","article-title":"The development of liquid biopsy for research and clinical practice in lymphomas: Report of the 15-ICML workshop on ctDNA","volume":"38","author":"Rossi","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1200\/JCO.21.01234","article-title":"Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study","volume":"40","author":"Luminari","year":"2022","journal-title":"J. Clin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/7\/1153\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:05:08Z","timestamp":1760029508000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/7\/1153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,29]]},"references-count":87,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["cancers17071153"],"URL":"https:\/\/doi.org\/10.3390\/cancers17071153","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,29]]}}}